Intestinal pathobiont bacterial species

Intestinal pathobionts are endogenous microorganisms that typically reside as harmless commensals within the gut but possess the potential to drive pathological processes under conditions of environmental stress or host immune dysfunction (Chow et al., 2011). Unlike obligate pathogens, pathobionts are permanent members of the human microbiota and often play roles in normal immune development and metabolic homeostasis (Round & Mazmanian, 2009). However, during states of dysbiosis, these organisms can expand and trigger chronic inflammation, contributing to the pathogenesis of diseases such as Inflammatory Bowel Disease (IBD), colorectal cancer, and metabolic syndrome (NIH). Therapeutic targeting of pathobionts is a burgeoning field, utilizing precision tools like bacteriophages (e.g., BX003) and defined microbial consortia (e.g., VE303) to selectively deplete harmful species while sparing the beneficial microbiota. This approach represents a shift from broad-spectrum antibiotics toward ecological restoration of the intestinal environment.

Other names

PathobiontsOpportunistic gut bacteriaCommensal pathogensDysbiotic microbiota

Therapeutic strategies involve the selective reduction of pathobiont populations via antibiotics or bacteriophages, or the restoration of microbial balance through competitive exclusion using Live Biotherapeutic Products (LBPs) (Chow et al., 2011; Round & Mazmanian, 2009).